Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¾ß°£ ÀÌ°¥ÀÌ¿Í ±³±Ùºñ´ë ȯÀÚÀÇ º¸Åø¸®´® µ¶¼Ò ÁÖ»ç È¿°ú

Nocturnal Bruxism and Botulinum Toxin Effect on the Subjects with Masseteric Hypertrophy

´ëÇѱ¸°­³»°úÇÐȸÁö 2007³â 32±Ç 3È£ p.337 ~ 346
¼Õ½Â¸¸, Á¤±âÁ¤, ±è¹ÌÀº, ±è±â¼®,
¼Ò¼Ó »ó¼¼Á¤º¸
¼Õ½Â¸¸ ( Sohn Seung-Mahn ) - ´Ü±¹´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­³»°úÇб³½Ç
Á¤±âÁ¤ ( Chung Gi-Chung ) - ´Ü±¹´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­¾Ç¾È¸é¹æ»ç¼±Çб³½Ç
±è¹ÌÀº ( Kim Mee-Eun ) - ´Ü±¹´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­³»°úÇб³½Ç
±è±â¼® ( Kim Ki-Suk ) - ´Ü±¹´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­³»°úÇб³½Ç

Abstract

º» ¿¬±¸´Â ±³±Ùºñ´ëÀÇ Áß¿äÇÑ ±â¿©¿äÀÎÀ¸·Î °£ÁֵǴ ÀÌ°¥ÀÌÀÇ ¿µÇâÀ» Æò°¡Çϱâ À§ÇØ ÀÌ°¥ÀÌ ½À°üÀÇ À¯¹«¿¡ µû¸¥ BTX-A ÁÖ»çÈÄÀÇ ÀÓ»óÀû º¯È­¸¦ Á¶»çÇÏ¿´´Ù.
½ÇÇèÀ» À§ÇØ ¾çÃø¼º ±³±Ùºñ´ë¸¦ °¡Áø Áö¿øÀÚ Áß, ¾ß°£ ÀÌ°¥ÀÌ ½À°üÀ» °¡Áö°í ÀÖ´Â Áö¿øÀÚ 5¸í°ú ÀÌ°¥ÀÌ ½À°üÀÌ ¾ø´Â Áö¿øÀÚ 5¸íÀ» ¼±ÅÃÇÏ¿© BTX-A(Allergen Inc., Botox¢ç)¸¦ 25 unit¾¿À» ¾çÃø ±³±Ù¿¡ °¢°¢ ÁÖ»çÇÏ¿´´Ù. BTX-AÀÇ ±³±ÙÁÖ»ç ÈÄ¿¡ ³ªÅ¸³ª´Â º¯È­¸¦ Æò°¡Çϱâ À§ÇÏ¿© ÁÖ»ç Àü°ú ÁÖ»ç ÈÄ 2ÁÖ, 4ÁÖ, 8ÁÖ, 3°³¿ù, 6°³¿ù 9°³¿ù¿¡ °¢°¢ °Ë»ç¸¦ ½ÃÇàÇÏ¿© ÃÊÀ½Æĸ¦ ÀÌ¿ëÇÑ ÀüÃøµÎ±Ù°ú ±³±ÙÀÇ µÎ²² ÃøÁ¤, ÀüÄ¡ºÎ¿Í ±¸Ä¡ºÎÀÇ ÃÖ´ë±³ÇÕ·Â ÃøÁ¤, ±³ÇÕ·ÂÀÇ º¯È­¿¡ ´ëÇÑ ÁÖ°üÀû Æò°¡¸¦ ºñ±³ÇÏ¿´´Ù.
±³±Ù¿¡ BTX-A¸¦ ÁÖ»çÇÑ ÈÄ¿¡ ÀÌ°¥À̱º°ú ºñÀÌ°¥À̱º ¸ðµÎ ÃÊÀ½Æİ˻翡¼­ ±³±ÙÀÇ µÎ²²°¡ °¨¼ÒµÇ¾î 3°³¿ù Á¤µµ¿¡ °¡Àå ÇöÀúÇÑ À§Ãà ¼Ò°ßÀ» º¸¿´À¸¸ç ÀÌÈÄ Á¡Â÷ ȸº¹µÇ¾î°¡´Â ¾ç»óÀ» º¸¿´´Ù(p£¼0.001). ºñÀÌ°¥À̱º°ú ºñ±³ ÇÏ¿´À» ¶§ ÀÌ°¥À̱º¿¡¼­ ±³±ÙµÎ²²ÀÇ È¸º¹ÀÌ ´õ ÇöÀúÇÏ¿´À¸³ª, ÁÖ»ç ÈÄ 9°³¿ù¿¡µµ Ä¡·áÀü°ú ºñ±³ÇßÀ» ¶§´Â ¿©ÀüÈ÷ ±ÙÀ§ÃàÀÌ °üÂûµÇ¾ú´Ù. ±¸Ä¡ºÎ ÃÖ´ë±³Çշµµ ±³±ÙµÎ²² º¯È­¿Í À¯»çÇÑ ¾ç»óÀ» º¸¿´´Ù. ÀüÃøµÎ±Ù°ú ÀüÄ¡ºÎ ÃÖ´ë ±³ÇÕ·ÂÀº ÁÖ»ç ÈÄ ½Ã°£°æ°ú¿¡ µû¸¥ º¯È­¸¦ º¸¿© ÁÖÁö ¾Ê¾Ò´Ù(p£¾0.05). ÇÇ°ËÀÚ°¡ ½º½º·Î ´À³¢´Â ±³ÇÕ·ÂÀº ÁÖ»ç 2ÁÖ ÈÄ¿¡ °¡Àå ÀúÇϵǾú´Ù°¡ Á¡Â÷ ºü¸£°Ô ȸº¹µÇ¾î 6°³¿ù¿¡¼­ 9°³¿ù »çÀÌ ÀÌÀüÀÇ »óÅ·Πȸº¹ÇÑ ¹Ý¸é ±³ÇÕ·ÂÃøÁ¤±â·Î ÃøÁ¤ÇÑ ±¸Ä¡ºÎ ÃÖ´ë±³ÇÕ·ÂÀÇ »ó´ëÀû º¯È­´Â ÃÖ´ë±³ÇÕ·ÂÀÌ ¿ø·¡ÀÇ »óÅ·Πȸº¹µÇÁö ¸øÇßÀ½À» º¸¿©ÁÖ¾ú´Ù. BTX-A ÁÖ»ç·Î ÀÎÇÑ »ó´ëÀûÀÎ ±¸Ä¡ºÎ ÃÖ´ë±³ÇÕ·ÂÀÇ ÀúÇÏ´Â ºñÀÌ°¥À̱º¿¡¼­ ´õ¿í ÇöÀúÇÏ°Ô °üÂûµÇ¾ú´Ù.
ÀÌ ½ÇÇèÀÇ °á°ú´Â ÀÌ°¥ÀÌ´Â BTX-A ÁÖ»ç ÈÄ¿¡ ¹ß»ýÇÑ ±³±Ù À§Ãà°ú ±³ÇÕ·Â °¨¼Ò°¡ ¿ø»óÅ·Πȸº¹µÇ´Â °úÁ¤¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖÀ½À» º¸¿©ÁØ´Ù. ±×·¯¹Ç·Î ÀÌ°¥ÀÌ µîÀÇ ÀÌ»ó±â´É ½À°üÀ» °¡Áø ±³±Ùºñ´ë ȯÀÚÀÇ BTX-A ÁÖ»çÈ¿°ú¸¦ º¸´Ù ¿À·¡ À¯ÁöÇϱâ À§Çؼ­ ÁÖ»ç¿Í ÇÔ²² ½À°üÁ¶ÀýÀ» À§ÇÑ ±³ÇÕÀåÄ¡ÀÇ »ç¿ëÀ» °í·ÁÇÒ ÇÊ¿ä°¡ ÀÖÀ» °ÍÀ¸·Î »ý°¢µÈ´Ù.

This study aimed to evaluate a relation of bruxism with clinical effects of botulinum toxin type A(BTX-A) injection. 5 bruxers and 5 nonbruxers with bilateral masseter hypertrophy were participated in this study. After injecting 25 unit of BTX-A(Allergen Inc, Botox¢ç) into each masseter muscle, the thickness of masseter(Mm) and anterior temporalis(Ta) muscles was measured by ultrasonography and the maximum bite force was evaluated during a 9-month period. Self-estimation on the recovery of occlusal force during mastication was done as well.
Regardless of presence of bruxsim, all subjects showed significantly reduced Ms thickness(p£¼0.001) and maximum bite force at 1st molars(p=0.027) with their peak at 3 months after injection, which then started to return. No significant difference was observed in Ta thickness and the bite force at the central incisors. While self-estimated occlusal force was the least at 2 weeks after injection and then rapidly returned to the baseline level with full recovery at the time of 6 to 9 months after injection, the maximum bite force measured by bite force recorder did not recover the original value, particularly in the nonbruxer group.
It is assumed that nocturnal bruxism can influence recovery of atrophic masseter and decreased occlusal force due to BTX-A injection. These findings suggest a need of occlusal appliance to control bruxism or clenching habit for longer clinical effect of BTX-A injection

Å°¿öµå

ÀÌ°¥ÀÌ;±³±Ùºñ´ë;º¸Åø¸®´®µ¶¼Ò;ÃÊÀ½ÆÄ°Ë»ç;±³ÇÕ·Â
Bruxism;Masseteric hypertrophy;Botulinum toxin;Ultrasonography;Occlusal(bite) force

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI